Adaptimmune Therapeutics PLC (ADAP) Income Tax Expense (Benefit) USD 2015 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2015 to 2024.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $526 K, a 15.8% decline year-over-year.
  • Adaptimmune Therapeutics PLC Income Tax Expense (Benefit) for the twelve months ending March 31, 2024 was $1.24 M, a 50.3% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2023 was $1.34 M, a 46.5% decline from 2022.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2022 was $2.5 M, a 216% increase from 2021.
  • Adaptimmune Therapeutics PLC annual Income Tax Expense (Benefit) for 2021 was $791 K, a 388% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $1.24 M $526 K -$99 K -15.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $1.34 M -$656 K -$1.65 M -166% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-06
Q3 2023 $2.99 M $687 K +$288 K +72.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $2.7 M $680 K +$210 K +44.7% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-09
Q1 2023 $2.49 M $625 K -$9 K -1.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $2.5 M $994 K +$785 K +376% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-06
Q3 2022 $1.71 M $399 K +$191 K +91.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $1.52 M $470 K +$394 K +518% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $1.13 M $634 K +$336 K +113% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $791 K $209 K +$157 K +302% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-06
Q3 2021 $634 K $208 K +$193 K +1287% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $441 K $76 K +$51 K +204% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $390 K $298 K +$228 K +326% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $162 K $52 K -$36 K -40.9% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-06
Q3 2020 $198 K $15 K -$72 K -82.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $270 K $25 K -$40 K -61.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 $310 K $70 K +$68 K +3400% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $242 K $88 K -$47 K -34.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-14
Q3 2019 $289 K $87 K -$46 K -34.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $335 K $65 K -$37 K -36.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $372 K $2 K -$125 K -98.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 $497 K $135 K +$305 K Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $192 K $133 K -$92 K -40.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $284 K $102 K -$63 K -38.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $347 K $127 K -$104 K -45% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-06
Q4 2017 $451 K -$170 K -$606 K -139% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-27
Q3 2017 $1.06 M $225 K +$121 K +116% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 $936 K $165 K -$128 K -43.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $1.06 M $231 K +$172 K +292% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q4 2016 $892 K $436 K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-27
Q3 2016 $104 K +$84 K +420% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-02
Q2 2016 $293 K +$146 K +99.3% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-03
Q1 2016 $59 K +$8 K +15.7% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q3 2015 $20 K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-10
Q2 2015 $147 K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-08
Q1 2015 $51 K Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.